Leading Medical Innovation through AI & Big Data

As a physician specializing in anesthesiology and pain medicine at Korea University Anam Hospital, I spent many years at my patients' side and repeatedly encountered the limits of frontline medical care. That experience is why I took on the role of CEO at GBI in 2023 and GB LABS in 2024, stepping into the digital healthcare business. Drawing on more than a decade of accumulated medical IT technology and telemedicine system development and operation know-how, GB LABS has worked to deliver trustworthy medical services without the constraints of time or space. Shifting medicine from a treatment-centered approach to one centered on prevention and management — that is why we focus on AI and digital technology.

By connecting four brands into a single ecosystem — the telemedicine platform DIGIDOC, the medical education platform MEDSENSE, the beauty and aesthetics brand EONNI, and our global distribution partner GBI Indonesia — we are building a new standard for Korean-style digital healthcare, starting in Southeast Asia where medical infrastructure remains insufficient. Close cooperation with domestic and international medical institutions, including Korea University Anam Hospital, has become a firm foundation of trust along that journey.

Going forward, GB LABS will keep thinking carefully to ensure technology is used not to replace people, but to narrow the distance between them. With deep gratitude and trust for every patient, partner, and colleague who walks with us, we ask for your continued interest and support as GB LABS takes its next steps.